Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chinook Therapeutics (Nasdaq: KDNY) announced the approval of employment inducement grants involving stock options for two new employees, totaling 83,599 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics (Nasdaq: KDNY) announced the approval of employment inducement grants involving stock options for two new employees, totaling 83,599 shares. These options have an exercise price of $15.54, aligned with the closing stock price on March 31, 2021. The options vest over four years, with an initial 25% vesting upon starting and subsequent monthly vesting. This decision aligns with Nasdaq listing Rule 5635(c)(4). Chinook focuses on precision medicines for kidney diseases, currently developing treatments for conditions like IgA nephropathy.
Positive
- Inducement grants signify growth and new talent acquisition.
- Stock options issued at current market price may boost employee motivation.
Negative
- None.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was -1.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia and SEATTLE, April 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 83,599 shares of common stock with a grant date of March 31, 2021 (the “Inducement Grants”) for two new employees.
The stock options approved under the Inducement Grants were issued on terms substantially similar to Chinook’s 2015 Equity Incentive Plan and have an exercise price per share equal to
The Company granted the stock options as a material inducement to these employees for entering into employment with Chinook Therapeutics, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.